Definitions
from The American Heritage® Dictionary of the English Language, 5th Edition.
- noun Proliferation of fibroblastic cells in bone marrow, causing anemia and sometimes enlargement of the spleen and liver.
from the GNU version of the Collaborative International Dictionary of English.
- noun (Med.) Fibrosis of the bone marrow.
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun A
myeloproliferative disorder of thebone marrow , in which the marrow undergoesfibrosis .
from WordNet 3.0 Copyright 2006 by Princeton University. All rights reserved.
- noun fibrosis of the bone marrow
Etymologies
from Wiktionary, Creative Commons Attribution/Share-Alike License
Support
Help support Wordnik (and make this page ad-free) by adopting the word myelofibrosis.
Examples
-
NEW ORLEANS ― A first-in-its class oral medication provides significant and durable relief for patients with a rare, debilitating and lethal bone marrow disorder called myelofibrosis, researchers at The University of Texas M.
-
NEW ORLEANS ― A first-in-its class oral medication provides significant and durable relief for patients with a rare, debilitating and lethal bone marrow disorder called myelofibrosis, researchers at The University of Texas M.
-
Abstracts already released suggest that the studies are going to point to much bigger potential for '424 beyond its lead indication myelofibrosis, which is already viewed as a blockbuster opportunity.
Healthcare Sector and Stocks Analysis from Seeking Alpha 2009
-
Incyte Corp.'s Jakafi pill obtained U.S. Food and Drug Administration approval Wednesday, making it the first drug approved specifically for myelofibrosis, a rare bone-marrow disease, according to the government agency.
FDA Approves Incyte's Drug for Bone-Marrow Disease Melodie Warner 2011
-
Novartis, based in Basel, Switzerland, said the study showed treatment with ruxolitinib, also known as INC424, provided a statistically significant reduction in spleen size in patients with different forms of myelofibrosis when compared with the best available therapy.
Novartis Blood-Cancer Drug Meets Goal Anita Greil 2011
-
*** Pharmaceuticals Novartis said an experimental drug for the treatment of myelofibrosis, a rare form of blood cancer, met the goals of a late-stage study, which should pave the way to file the drug for regulatory approval in the second quarter.
Business Watch 2011
-
An enlarged spleen is one of the characteristics of myelofibrosis.
Novartis Blood-Cancer Drug Meets Goal Anita Greil 2011
-
The bone marrow of people with myelofibrosis is replaced by scar tissue, which can cause an enlarged spleen, anemia, decreased white blood cells and platelets.
FDA Approves Incyte's Drug for Bone-Marrow Disease Melodie Warner 2011
-
ZURICH— Novartis AG said Tuesday an experimental drug for the treatment of myelofibrosis, a rare form of blood cancer, met the goals of a late-stage study, which should pave the way to begin filing the drug for regulatory approvals in the second quarter.
Novartis Blood-Cancer Drug Meets Goal Anita Greil 2011
-
The cause of myelofibrosis is unknown, and there are few treatment options.
Novartis Blood-Cancer Drug Meets Goal Anita Greil 2011
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.